Cvi Holdings, LLC Altimmune, Inc. Transaction History

Cvi Holdings, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $83,104 - $150,732	-10,600 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$9.93 - $33.26 $186,684 - $625,288	-18,800 Reduced 63.95%	10,600 $140,000
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $85,260 - $314,874	29,400 New	29,400 $315,000
Q4 2018 Feb 14, 2019	SELL	$1.72 - $7.24 $159,560 - $671,640	-92,768 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$4.27 - $26.23 $396,119 - $2.43 Million	92,768 New	92,768 $408,000

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $325M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Cvi Holdings, LLC, based on Form 13F filings with the SEC.

Stay updated on Cvi Holdings, LLC with notifications on news.